---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-291443"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2025-11-21T23:59:59+00:00"
generated_at: "2026-05-16T17:40:03.275464+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Inhibikase raises ~$93.6M in public offering, advances IKT-001 to Phase 3 PAH trial

## Summary
- Offering of 46.1M shares at $1.45/share and pre-funded warrants for 22.9M shares; net proceeds ~$93.6M.
- Underwriters granted 30-day option to purchase up to 10.3M additional shares.
- Company amended Series A-1 and B-1 warrants to reflect plan to advance IKT-001 to global pivotal Phase 3 trial in PAH.
- Offering expected to close November 24, 2025; shelf registration effective June 27, 2025.
- Jefferies, BofA Securities, and Cantor Fitzgerald are representatives of the underwriters.

## SEC filing metadata
- accession: 0001193125-25-291443
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2025-11-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312525291443/0001193125-25-291443-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312525291443/d65626d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-291443
- JSON: https://secwatch.observer/filing/0001193125-25-291443.json
- Plain text: https://secwatch.observer/filing/0001193125-25-291443.txt

## Key facts
- Material Agreements
  Inhibikase Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, BofA Securities, Inc. and Cantor Fitzgerald & Co., as representatives of the several underwriters (effective 2025-11-20).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Jefferies LLC, BofA Securities, Inc. and Cantor Fitzgerald & Co., as representatives of the several underwriters
  - Effective: 2025-11-20
  source text: On November 20, 2025, Inhibikase Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, BofA Securities, Inc. and Cantor Fitzgerald & Co., as representatives of the several underwriters listed on Schedule A thereto (collectively, the “Underwriters”), relating to an underwritten public offering (the “Offering”) of (i) 46,091,739 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and (ii) in lieu of Common Stock to certain investors, pre-funded warrants to purchase up to an aggregate of 22,873,779 shares of Common Stock (the “Pre-Funded Warrants” and the Common Stock issuable upon exercise of the Pre-Funded Warrants, the “Warrant Shares”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312525291443/0001193125-25-291443-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.